Published in Cancer Res on June 15, 2008
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res (2009) 2.79
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell (2011) 2.30
The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol (2011) 2.16
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov (2013) 1.93
In vivo animal models for studying brain metastasis: value and limitations. Clin Exp Metastasis (2013) 1.52
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. Clin Cancer Res (2014) 1.46
A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis. Cancer Cell (2017) 1.39
Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer (2010) 1.31
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther (2010) 1.30
Transmigration of melanoma cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine proteases. PLoS One (2011) 1.11
Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer (2010) 1.07
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia (2010) 1.05
A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med (2008) 1.03
Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res (2012) 1.01
Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol (2010) 0.95
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res (2009) 0.95
Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer. PLoS One (2013) 0.95
Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol (2015) 0.87
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer (2011) 0.83
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Mol Med (2014) 0.83
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther (2015) 0.83
First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study. Invest New Drugs (2011) 0.82
In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis. Front Oncol (2013) 0.81
Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res (2016) 0.81
Melanoma brain metastases: an unmet challenge in the era of active therapy. Curr Oncol Rep (2013) 0.80
Development and characterization of a clinically relevant mouse model of melanoma brain metastasis. Pigment Cell Melanoma Res (2013) 0.79
Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. J Cancer Res Clin Oncol (2010) 0.78
A synthetic modular approach for modeling the role of the 3D microenvironment in tumor progression. Sci Rep (2015) 0.76
Comment re: Preclinical model of spontaneous melanoma metastasis. Cancer Res (2009) 0.75
Establishment and Validation of an Orthotopic Metastatic Mouse Model of Colorectal Cancer. ISRN Hepatol (2013) 0.75
Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. Int J Mol Sci (2016) 0.75
Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note. PLoS One (2016) 0.75
Drug Delivery to Melanoma Brain Metastases: Can Current Challenges Lead to New Opportunities? Pharmacol Res (2017) 0.75
Mouse models of metastasis: progress and prospects. Dis Model Mech (2017) 0.75
Preclinical Modeling and Therapeutic Avenues for Cancer Metastasis to the Central Nervous System. Front Oncol (2017) 0.75
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science (2004) 5.64
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 4.79
The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer (2006) 4.55
Raising the bar for cancer therapy models. Nat Biotechnol (2010) 4.52
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 4.41
Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell (2010) 4.32
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A (2007) 4.08
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol (2011) 3.58
Relative and absolute quantification of postsynaptic density proteome isolated from rat forebrain and cerebellum. Mol Cell Proteomics (2006) 3.56
Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol (2012) 3.51
Soy isoflavones in the prevention of menopausal bone loss and menopausal symptoms: a randomized, double-blind trial. Arch Intern Med (2011) 3.11
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res (2003) 3.09
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet (2011) 2.85
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 2.80
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res (2009) 2.79
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res (2006) 2.78
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res (2002) 2.69
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A (2009) 2.66
Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. Nat Cell Biol (2011) 2.65
Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer (2011) 2.42
Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res (2007) 2.35
miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell (2011) 2.30
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res (2002) 2.27
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res (2009) 2.23
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A (2003) 2.20
A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A (2002) 2.16
The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem (2008) 2.09
Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J Cell Biol (2007) 2.07
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol (2008) 2.06
Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell (2008) 1.94
Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J (2004) 1.93
Enhanced 2,3-butanediol production by Klebsiella pneumoniae SDM. Appl Microbiol Biotechnol (2008) 1.92
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther (2011) 1.87
Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation. Hepatology (2008) 1.83
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood (2005) 1.80
A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res (2004) 1.79
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res (2008) 1.78
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res (2004) 1.77
Ogg1 knockout-associated lung tumorigenesis and its suppression by Mth1 gene disruption. Cancer Res (2003) 1.75
Acetoin metabolism in bacteria. Crit Rev Microbiol (2007) 1.73
Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res (2006) 1.70
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood (2006) 1.69
Structure dissection of human progranulin identifies well-folded granulin/epithelin modules with unique functional activities. Protein Sci (2008) 1.60
Quantum teleportation and entanglement distribution over 100-kilometre free-space channels. Nature (2012) 1.56
Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res (2002) 1.56
Activated expression of an Arabidopsis HD-START protein confers drought tolerance with improved root system and reduced stomatal density. Plant Cell (2008) 1.53
Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res (2007) 1.52
Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS One (2007) 1.52
Adhesion molecule-dependent mechanisms regulate the rate of macrophage clearance during the resolution of peritoneal inflammation. J Exp Med (2002) 1.51
Racial ethnic differences in rates and determinants of deceased donor kidney transplantation. J Am Soc Nephrol (2011) 1.48
Polyubiquitin linkage profiles in three models of proteolytic stress suggest the etiology of Alzheimer disease. J Biol Chem (2011) 1.48
Systematic approach for validating the ubiquitinated proteome. Anal Chem (2008) 1.47
Non-sterilized fermentative production of polymer-grade L-lactic acid by a newly isolated thermophilic strain Bacillus sp. 2-6. PLoS One (2009) 1.46
Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. Clin Cancer Res (2005) 1.44
Physicochemical properties of cross-linked poly-gamma-glutamic acid and its flocculating activity against kaolin suspension. J Biosci Bioeng (2005) 1.43
Polyubiquitination of prolactin receptor stimulates its internalization, postinternalization sorting, and degradation via the lysosomal pathway. Mol Cell Biol (2008) 1.41
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res (2004) 1.40
High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res (2002) 1.40
The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26 s proteasome. J Biol Chem (2009) 1.39
Efficient internalization of MHC I requires lysine-11 and lysine-63 mixed linkage polyubiquitin chains. Traffic (2009) 1.39
Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res (2006) 1.39
Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev (2011) 1.38
A novel gene, encoding 6-hydroxy-3-succinoylpyridine hydroxylase, involved in nicotine degradation by Pseudomonas putida strain S16. Appl Environ Microbiol (2008) 1.38
On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev (2007) 1.37
Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. Mol Cell (2011) 1.37
Georgenia ruanii sp. nov., a novel actinobacterium isolated from forest soil in Yunnan (China), and emended description of the genus Georgenia. Int J Syst Evol Microbiol (2007) 1.34
Characterization of environmentally friendly nicotine degradation by Pseudomonas putida biotype A strain S16. Microbiology (2007) 1.34
Novel nicotine oxidoreductase-encoding gene involved in nicotine degradation by Pseudomonas putida strain S16. Appl Environ Microbiol (2008) 1.33
Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res (2005) 1.31
Production of 2,3-butanediol from corncob molasses, a waste by-product in xylitol production. Appl Microbiol Biotechnol (2010) 1.31